Topoisomerase IIα mRNA and tumour cell proliferation in non-Hodgkin's lymphoma

Journal of Clinical Pathology

Volumn 50, Issue 1, 1997, Pages 22-26

  Lohri, A ^a   Reuter, J ^a   Gudat, F ^b   Herrmann, R ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Ki 67 immunostaining; non Hodgkin's lymphoma; Topoisomerase II mRNA

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); MESSENGER RNA; MONOCLONAL ANTIBODY KI 67;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN TISSUE; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031036206     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.50.1.22     Document Type: Article

References (23)

1. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13 20.
2. Brittinger G, Bartels H, Common H, Duhmke E, Fulle HH, Gunzer U, et al. Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas. Results of a prospective multicenter study by the Kiel lymphoma study group. Hematol Oncol 1984;2:269 306.
3. NCI non-Hodgkin's Classification Project Writing Committee. Classification of non-Hodgkin's lymphomas. Reproducibility of major classification systems. Cancer 1985;55:91 5.
4. Harris NL, Jaffe ES, Stein H, Banks BM, Chan JKC, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361 02
5. Hofmann GA, Mattern MR. Topoisomerase II in multiple drug resistance. Gytotechnology 1993;12:137-54.
6. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989;28:8154 60.
7. Evans CD, Mirski SE, Danks MK, Cole SPC. Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line. Cancer Chemother Pharmacol 1994;34:242-8.
8. Van Hille B, Lohri A, Reuter J, Herrmann R. Nonradioactive quantification of mdr1-mRNA by polymerase chain reaction amplification coupled with HPLC. Clin Chem 1995;41:1087 93.
9. Shipp M. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project, N Engl J Med 1993;329:487-94.
10. Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 1989;86: 9431 5.
11. Nakajima Iijima S, Hamada H, Reddy P, Kakunaga T. Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns. Proc Natl Acad Sci USA 1985;82:6133-7.
12. Cole SPC, Chanda ER, Dicke FP, Gerlach JH, Mirski SEL. Non-p-glycoprotein mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 1991;51:3345 52.
13. Kaufmann SH, McLaughlin SJ, Kasten MB, Liu LF, Karp JE, Burke PJ. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 1991;51:3534-43.
14. Sullivan DM, Glisson BS, Hodges PK, Smallwood-Kentro S, Ross WE. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 1986;25:2248 56.
15. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994;83: 517-30.
16. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991;51:6592 5.
17. Beck J, Niethammer D, Gekeler V. High mdr1- and mrp-, hut low topoisomerase II alpha-gene expression in B-cell chronic lymphocytic leukaemias. Cancer Lett 1994;86:135 42.
18. McKenna SL, West RR, Whittaker JA, Padua RA, Holmes JA. Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome. Leukemia 1994;8:1498-502.
19. Stammler G, Sauerbrey A, Volm M. Messenger RNA expression of resistance factors and their correlation to the proliferative activity in childhood acute lymphoblastic leukemia. Cancer Lett 1995;89:129 35.
20. Gerdes J, Stein H, Pileri S, Rivano MT, Gobbi M, Raltkiaer E, et al. Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas [letter]. Lancet 1987;ii:448-9.
21. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 1994;83:1460 6.
22. Hall PA, Richards MA, Gregory WM, d'Ardenne AJ, Lister TA, Stansfeld AG. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 1988;154: 223-35.
23. Boege F, Andersen A, Jensen S, Zeidler R, Kreipe H. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxyterminal epitope with peptide antibodies. Am J Pathol 1995;146:1302 8.